- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity | 2 | Pharmaceutical Technology | ||
| 16.09. | Bicara Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.09. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | 52 | GlobeNewswire (Europe) | BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients... ► Artikel lesen | |
| 13.09. | Bicara Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.09. | Bicara, MBX Bio lead gainers as biotech trio makes trading debut | 2 | Seeking Alpha | ||
| 13.09. | backed Bicara Therapeutics shares surge 46% in stellar market debut | 1 | Reuters | ||
| 13.09. | Bicara Therapeutics Opens at $26.25, Upsized IPO Priced at $18 | 2 | Investing.com | ||
| 13.09. | backed Bicara Therapeutics shares jump 45.8% in stellar market debut | 1 | Reuters | ||
| 13.09. | Oncology biotech Bicara Therapeutics prices upsized IPO at $18, the high end of the range | 1 | Renaissance Capital | ||
| 13.09. | Zenas, MBX and Bicara all head to Nasdaq in hot day for biotech IPOs | - | FierceBiotech | ||
| 13.09. | Bicara Leads Trio of US Biotech IPOs Raising $703 Million | 1 | BNN Bloomberg | ||
| 13.09. | Bicara Therapeutics prices upsized $315M offering | 1 | Seeking Alpha | ||
| 13.09. | Bicara Therapeutics Prices IPO Of 17.50 Mln Shares At $18.00/shr | 1 | RTTNews | ||
| 13.09. | Bicara Therapeutics raises $315 million in US IPO | 1 | Reuters | ||
| 13.09. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering | 257 | GlobeNewswire (Europe) | BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients... ► Artikel lesen | |
| 12.09. | Bicara Therapeutics targets $265 million proceeds in upsized US IPO | 1 | Reuters | ||
| 11.09. | Bicara Therapeutics upsizes IPO | 1 | Seeking Alpha | ||
| 11.09. | Oncology biotech Bicara Therapeutics increases shares offered 25% ahead of $250 million IPO | 1 | Renaissance Capital | ||
| 11.09. | Bicara Therapeutics Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 10.09. | Bicara Therapeutics Inc. - 8-A12B, Registration of securities | 1 | SEC Filings |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,090 | -2,30 % | Biotech Report: Biontech gesucht, Qiagen behauptet | (shareribs.com) Frankfurt / New York 16.09.2024 - Biotech-Aktien zeigten sich zum Wochenauftakt im deutschen Handel uneinheitlich. Für Biotest und Evotec ging es abwärts. Qiagen konnten sich behaupten.... ► Artikel lesen | |
| ELIEM THERAPEUTICS | 8,430 | +1,81 % | Eliem therapeutics executive sells over $9,000 in company stock | ||
| ARVINAS | 25,630 | +0,12 % | Arvinas Inc.: Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer | - Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology... ► Artikel lesen | |
| EVOTEC | 6,005 | -5,36 % | Aurubis, BMW, Elmos, Evotec, freenet, TUI u.a. - Aktien-Positionen der Shortseller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| ARCELLX | 86,65 | +1,42 % | ACLX, HROW Deliver Triple-Digit Returns - Did You Cash In? | WASHINGTON (dpa-AFX) - Many traders seek instant gratification in the stock market. Some stocks offer quick profits, while others require a patient, long-term approach for significant returns.... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 24,350 | +5,14 % | ROUNDUP/Aktien New York: Neue Rekorde vor US-Zinsentscheid | NEW YORK (dpa-AFX) - Vor dem Zinsentscheid der US-Notenbank Fed bleiben die Anleger an den New Yorker Börsen optimistisch. Der Leitindex Dow Jones Industrial markierte am Dienstag gleich zu Beginn... ► Artikel lesen | |
| DYNE THERAPEUTICS | 36,580 | +0,47 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 34,410 | -2,66 % | SpringWorks Therapeutics, Inc.: FDA Grants Priority Review to SpringWorks Therapeutics' New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN | - PDUFA target action date of February 28, 2025 - - EU Marketing Authorization Application also validated by European Medicines Agency - STAMFORD, Conn., Aug. 28, 2024 (GLOBE NEWSWIRE) -- SpringWorks... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,670 | -1,42 % | Jones Trading stuft Beam Therapeutics auf "Halten" ein | ||
| ADMA BIOLOGICS | 19,950 | +1,06 % | EWTX Yields Over 300% Returns, ADMA Records 200% Gains - Did You Strike While The Iron Is Hot? | WASHINGTON (dpa-AFX) - Biotech investing is a high-stakes game that may not suit the faint-hearted due to its inherent volatility. However, this sector can offer astronomical returns when investors... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 58,66 | +10,78 % | Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer | SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated... ► Artikel lesen | |
| VERA THERAPEUTICS | 42,780 | +1,88 % | Vera Therapeutics director sells over $696k in company stock | ||
| RECURSION PHARMACEUTICALS | 6,810 | -1,87 % | Angle PLC Announces Agreement with Recursion Pharmaceuticals | New pharma agreement for Parsortix CTC analysisGUILDFORD, SURREY / ACCESSWIRE / September 19, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating... ► Artikel lesen | |
| IMMUNOVANT | 29,240 | -1,18 % | Immunovant Inc.: Immunovant Provides Update on Graves' Disease Development Program | High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12High dose batoclimab achieved 56% ATD-Free response rate in patients uncontrolled on... ► Artikel lesen | |
| NURIX THERAPEUTICS | 25,630 | +2,27 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update | Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with appointment... ► Artikel lesen |
Das Unternehmen BICARA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 25,470 Euro und damit +3,54 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BICARA THERAPEUTICS INC finden Sie auf Wallstreet Online.
